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Abstract
Objective-To evaluate the prevalence of
"high risk" human papillomavirus type
16 (HPV 16) in transitional cell carci-
noma ofthe urinary bladder.
Matenials and methods-The study
included 10 biopsy specimens from male
patients of transitional cell carcinoma of
the urinary bladder for the detection of
HPV DNA sequences. Specimens were
collected from the Urology Clinic of the
K.G. Medical College Hospital, Lucknow,
India. Detection of HPV DNA was car-
ried out by tissue in situ hybridisation (a
single copy gene localisation method)
using 3H-labelled HPV DNA probe and
alsb by polymerase chain reaction (PCR)
techniques using primers to HPV 16
upstream regulatory region (URR).
Results-Out of 10 cases of transitional
cell carcinoma of the urinary bladder,
"high risk" HPV 16 DNA was detected
only in one (10%) by using in situ hybridi-
sation whereas two cases (20%) were
found to be positive by polymerase chain
reaction.
Conclusion-Our results suggest that the
rare occurrence ofHPV in bladder carci-
noma may not have a causal relation with
the viral infection.
(Genitourin Med 1995;71:231-233)
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sitional cell carcinoma has been detected by in
situ hybridisation"3 and polymerase chain
reaction.'4 But most surprisingly, a very high
prevalence of HPV (81%), particularly the
high risk (16 & 18) types (62%) in bladder
carcinomas has been reported'" recently from
Japan. In India, the incidence of HPV, partic-
ularly the type 16 in cancer of the uterine
cervix is very high (> 90%) in women.'6
However, so far no report on HPV prevalence
in bladder carcinoma has been available from
the Indian population. Since genital condylo-
mata can easily extend to the urethra and uri-
nary bladder,46 17 it is not unlikely that HPV
infection will be found in these organs. The
present study has been carried out to detect
HPV DNA in cancer of the urinary bladder
in men using both in situ hybridisation and
polymerase chain reaction.
Materials and methods
The study comprised histopathologically con-
firmed 10 cases of transitional cell carcinoma
(TCC) of the urinary bladder in grade II and
III subjected to HPV DNA detection by both
in situ hybridisation and polymerase chain
reaction. Out of 10 cases, 7 were papillary
TCC, 2 solid TCC and one was a mixture of
both. These cases were registered at the
Urology Clinics, K.G. Medical College
Hospital, Lucknow. Paraffin embedded tissue
sections were used for the in situ hybridisation
as well as for the extraction of DNA for the
polymerase chain reaction.
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Introduction
Although about 70 human papillomavirus
(HPV) genotypes have been associated with
benign, premalignant and malignant lesions of
the anogenital tract and many other organ
sites in humans, the involvement of these
viruses particularly of "high risk" HPV types
16 and 18 in urinary bladder carcinoma is not
clearly understood. Detection of bovine papil-
lomavirus (BPV) in bladder carcinoma of
cattle,' 2 the presence of HPV specific condy-
lomatous lesions'- and HPV antigens in cancer
of the bladder in humans7 suggest the pres-
ence of HPVs in these carcinomas. This has
been further strengthened by experimental
evidence that injection of cutaneous BPVs
into the submucosa of urinary bladder lead to
development of fibroma.' 8 Also, HPV DNA
has been detected in prostate cancer9 and
urine samples of men'0"1 and women.'2
Recently, a low frequency of HPV 16 in tran-
Tissue in situ hybridisation
In situ hybridisation for the detection of HPV
DNA in paraffin embedded tissue sections
was performed according to the protocols
described earlier by us.'9 Vector-free 8 kb
HPV 16 DNA insert was nick-translated with
3H dCTP, dATP and dTTP (Amersham,
England) to a specific activity of 1 x 108
cpm/,ug DNA and was used as probe.
Following hybridisation, slides were coated
with Kodak NTB2 nuclear track emulsion
(Kodak & Co., USA), incubated for 4 to 6
weeks at 4°C and developed in D19B devel-
oper. Haematoxylin-eosin stained slides were
examined under oil immersion for the pres-
ence of silver grains over the cell nuclei as an
index ofHPV DNA positivity.
DNA extraction and polymerase chain reaction
DNA extraction from paraffin sections and
polymerase chain reaction (PCR) were carried
out according to the methods described earlier
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Figure 1 (a, b): ISH of
urinary bladder carcinoma
tissue sections (a, b) with
3H-labelled HPV 16 DNA
probe using the singk copy
gene localization method.
Of 10 bladder cancer
tissues analysed only 1
(10%) containedHPV 16
DNA. Presence ofHPV
DNA was indicated by
deposition ofsilver grains
over the nuclei. The
sections were stained with a
H and Efollowing
hybridisation.
Figure 2 PCR
amplification of
oligonucleotide primers
from the conserved URR
region ofHPV 16 showing
217 bp amplimer. First
lane is Hae III-digested
MX174 DNA size marker.
Second lane is HPV 16
plasmid DNA, the lanes 1
to 10 are urinary bladder
carcinoma DNA samples
showing HPV 16 specific
amplification of217 bp in
only 2 samples (Canes 2
and 4).
Figure 3 PCR
amplification of
oligoprimers from human
(3-globin gene which served
as an experimental control.
Lanes 1 to 8, all urinary
bladder carcinoma DNA,
showing 268 bp 13-globin
gene amplification. Lane 8
is HPV 16 positive bladder
carcinoma sample showing
amplification of both ,B
globin gene (268bp) as
weIas HPV 16 DNA
(217bp). First three lanes
are Hae III-digested
0X174 DNA size
markers, HPV 16 plasmid
DNA and distilled water
showing no globin gene
amplification respectively
0
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was used as internal experimental control.
Twenty microlitres of PCR amplified prod-
ucts were run on 3% Nusieve agarose gel
(FMC BioProducts, Rock Land, USA) along
with Hae III-digested 0X174 DNA marker.
Gels were stained in ethidium bromide and
photographed by a UV transilluminator.
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by US."6 1821 Two oligo nucleotide primers
from the upstream regulatory region (URR)
of HPV 16 have been used. (P1, 5'- AAG
GCC AAC TAA ATG TCA C -3' and P2,
5'-CTGCTTTTATACTAACCGG-3').
These primers allow amplifications of the
region between nucleotides 7765 and 75 and
an amplimer of 217 base-pairs. J-globin gene
showing amplification of the 268bp fragment
Results
Both in situ hybridisation (ISH) and PCR
techniques have been used to detect the pres-
ence of HPV 16 DNA sequences in 10 histo-
logically confirmed transitional cell carcinoma
of the urinary bladder. Out of 10 cases of
transitional cell carcinoma only one was posi-
tive by ISH whereas using polymerase chain
reaction, HPV 16 DNA was detected in two
cases. Figure 1 (a, b) shows the HPV 16 DNA
positivity by radioactive ISH in the transi-
tional cell carcinoma of the urinary bladder.
The presence of silver grains can be seen in
the majority of cell nuclei (arrows).
Figure 2 shows the HPV 16 DNA positivity
in two out of ten bladder carcinoma cases
analysed by PCR. An amplified PCR product
of 217 bp fragment can be seen in the ethid-
ium bromide stained 3% Nusieve agarose gel.
Lanes 1-10 are the bladder tumour DNA
samples of which lanes 2 and 4 show HPV 16-
specific 217bp amplification. The first two
lanes on the extreme left represent Hae III-
digested 0X174 DNA marker and HPV-16
plasmid DNA amplification respectively.
Amplification of ,l-globin gene (268bp) which
served as an internal control for the experi-
ments is shown in fig 3. Lanes 1 to 8 are blad-
der carcinoma showing amplification of
,8-globin-specific 268bp fragment. Lane 8 is
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an HPV positive sample showing both
fl-globin and HPV specific bands. Of the
three lanes on the left, the first is Hae III-
digested 0X174 DNA size marker, the other
two lanes run with HPV plasmid DNA and
distilled water do not show,B-globin ampli-
fication respectively. In the present study,
HPV 16 DNA frequency by ISH was found to
be one in 10 as compared with 2 in 10 by
PCR. Since the number of the cases analysed
was small, no statistical analysis was
employed.
Discussion
Carcinoma of the urinary bladder is one of the
prevalent cancer among males and has been
associated with many risk factors for the
development of this disease.22 24 Although
immunological demonstration of papillo-
mavirus common structural antigens7 25 26 and
observation of HPV-specific cytomorphologi-
cal features of koilocytotic atypia27-30 in uri-
nary bladder carcinomas have provided
sufficient ground to believe that HPV may be
involved in these tumours, several previous
studies have failed to demonstrate HPV DNA
in them.3' 32 There have been reports of the
presence of condylomatous lesions indicative
of HPV 6 and 11 infection28 29 and also of a
case of bladder carcinoma showing HPV 16
positivity with mild immunodeficiency and
genital warts.'7 However, the involvement of
"high risk" HPV types 16 and 18 in carci-
noma of the urinary bladder has not been
established. Recently, there have been two
reports showing a low incidence of human
papillomavirus type 16 DNA in urinary blad-
der tumours.'3 14 In the present study, we have
also observed a very low prevalence of HPV
16 in transitional cell carcinoma of the urinary
bladder by both ISH and PCR. Our observa-
tions are in good agreement with the earlier
reports. But in sharp contrast to these findings
including this report, recently Anwar et all5
using PCR assay reported a very high preva-
lence (81%) of HPV in bladder carcinomas as
well as in normal urinary bladder specimens
(33%). The frequency of "high risk" HPV
types-16, 18 and 33 was also found to be
very high (62%), a rate much higher than that
reported for cervical carcinomas (44%) in
Japan.33 It is difficult at present to ascertain such
a high prevalence of HPV in urinary bladder
carcinoma. This may be because of either
technical problems associated with PCR
detection of HPV or geographical variations in
HPV prevalence. Further study from Japan and
other regions would throw light on this aspect.
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